✦ LIBER ✦

Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer

✍ Scribed by A. Arakawa; H. Nishikawa; K. Suzumori; N. Kato

Publisher: Springer
Year: 2001
Tongue: English
Weight: 126 KB
Volume: 6
Category: Article
ISSN: 1341-9625
DOI: 10.1007/pl00012113

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic and pharmacodynamic anal

Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and cyclophosphamide in patients with gynecological cancers

✍ A. Arakawa; Kaoru Suzumori; Noriko Kato; Hidekazu Asai; Kenji Suzumori; Seiji Ha 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 120 KB

Sorafenib in combination with carboplati

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

✍ Martin Pölcher; Meike Eckhardt; Christoph Coch; Matthias Wolfgarten; Kirsten Küb 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 203 KB

Clinical trial and pharmacokinetic study

Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer

✍ Ritsu Yamamoto; Masanori Kaneuchi; Masashi Nishiya; Yukiharu Todo; Mahito Takeda 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 95 KB

Combination chemotherapy with weekly pac

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

✍ Tomihiko Yasufuku; Katsumi Shigemura; Osamu Matsumoto; Soichi Arakawa; Masato Fu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 168 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects ofCYP3A5andMDR1polymorphisms in patients with urogenital cancers

✍ Mari Jiko; Ikuko Yano; Eriko Sato; Kazushige Takahashi; Hideyuki Motohashi; Sato 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 339 KB

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c